ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lurasidone

Also written as “Lurasidone”, “Lurasidone HCl” and “SM-13496”.

Its studies are mostly in Schizophrenia · Bipolar Disorder · Depressive Disorder, Major · Depression · Urinary Tract Infections, led by 4 companies.

Drug pageLurasidone: every studyAll 66 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 7, 202152 company-led studies, 2 open or runningNext primary completion: Oct 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sumitomo Pharmaits history only480 open or runningphase 4since Aug 7, 2021Aug 16, 2002none ahead
Bukwang Pharmaceutical21 open or runningphase 3since Mar 8, 2018Mar 8, 2018Oct 2027phase 3 · NCT07781293
NeuroRxits history only11 open or runningphase 2since Nov 7, 2023Nov 7, 2023none ahead
Standard Chem. & Pharm.its history only10 open or runningphase 4since Dec 20, 2017Dec 20, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bukwang Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 8, 2018First study: phase 3 study in SchizophreniaFirst studyNCT03465787 · 210 enrolled · Korea, Republic of
  2. Aug 6, 2026Phase 3 study in Depressive Disorder, MajorNCT07781293 · 364 planned

Ahead

  1. Oct 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT07781293

TargetBeta

DRD2 →HTR2A →read by rule
“Serotonin 2a (5-HT2a) receptor antagonist; Dopamine D2 receptor antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131
RisperidoneruleJohnson & Johnsonphase 4111
paliperidoneruleJohnson & Johnsonphase 4106
OlanzapineruleEli Lillyphase 476
brexpiprazoleruleOtsukaphase 470
iloperidoneruleVanda Pharmaceuticalsphase 415
lumateperoneruleJohnson & Johnsonphase 325

Studies

All 2 Bukwang Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07781293Depressive Disorder, Major3Not yet recruitingOct 2027364
NCT03465787Schizophrenia · Korea, Republic of3CompletedOct 26, 2022210

How it is read

Names in the registry

  • “Lurasidone”, 22 entries
  • “Lurasidone HCl”, 10 entries
  • “SM-13496”, 4 entries
  • “Lurasidone 40 mg”, 3 entries
  • “lurasidone”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.